Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s GSK patents relating to its respiratory syncytial virus (RSV) vaccine. Also Read: UK Chooses ...